moder depend complement high
messag report result ahead con complement
franchis soliri ultomiri key driver lead management rais full
year revenu guidanc meanwhil metabol portfolio show
sign moder growth price headwind expect remaind
year management done good job build pipelin think meaning data
readout pipelin month away henc see limit upsid
near term reiter neutral increas p/e-bas pt
soliri sale posit expect high singl digit unit growth pnh/ahu mg
nmo addit growth driver
soliri sale posit healthi volum growth soliri sale look good
come q/q y/i ahead consensu though
benefit tender order without one-tim benefit sale beat
consensu y/i volum growth note soliri gener
healthi volum growth last month quarterli y/i volum growth
respect indic
continu robust uptak soliri approv indic addit manag
note expect unit growth core pnh/ahu indic
high-singl digit rang mg nmo provid addit growth beyond
mg growth continu ad new gmg patient vs
come total gmg soliri patient end quarter soliri rate
adopt gmg robust far reduct rate growth
past quarter expect lower number absolut patient ad
could indic gmg growth moder
guggenheim secur llc research compani report
track achiev patient soliris/ultomiri manag
previous note end pnh ahu patient soliri
 base number actual sale growth pnh/ahu
estim pnh/ahu patient soliri
addit know mg patient drug bring total
estim patient soliri manag note expect
end patient would impli total patient
ad estim pnh/ahu patient ad
given moder growth see pnh/ahu patient ad realist
remain come gmg seem achiev
page analyst certif import disclosur
upcom nmosd pdufa next key mileston recal soliri
upcom pdufa nmosd june receiv prioriti review base
outstand phase result prevent studi show patient
relapse-fre week nmosd present larg opportun compani given
exist weak soc address popul view approv
like manag note nmo addit growth driver soliri
pre-launch intern train field medic team current underway
note current approv therapi nmosd mani patient
current treat rituxan given sever diseas alxnmay
encount patient resist switch therapi thu may
work cut win new patient
ultomiri long-lif antibodi convers rate look posit first full quarter
market addit ultomiri indic gain steam
ultomiri strong ultomiri impress first full quarter
market gener sale soundli beat consensu
given current pnh patient convers rate per month think
remain patient convert convert
soliris-to-ultomiri next month well ahead manag goal year
ultomiri sale project tweak reflect rate
ultomiri ahu snda submit april ahu file base posit
top-line result pivot phase studi demonstr complet tma
respons complement inhibitor nave ahu patient see press releas
addit regulatori file eu japan expect later year phase
studi ultomiri children/adolesc ahu patient current underway
phase ultomiri studi gmg subq formul begun alexion
initi pivot phase mg trial ultomiri view
key ultomiri indic go forward later-stag competit could gener
commerci battl mg could impact ultomiri uptak diseas meanwhil
pk-base phase studi subq ultomiri per week dose pnh/ahu
begun enrollment/treat data expect earli
metabol show moder growth strensiq ert kanuma lal-
ert weaker quarter strensiq come y/i growth
y/i volum growth consensu kanuma came
y/i growth y/i volum growth consensu
despit tender order addit new price strategi surround
weight-bas dose regimen go provid headwind throughout
price headwind attribut metabol henc reduc project
strensiq sale year meanwhil kanuma continu disappoint despit
concert effort increas payor/physician educ
fcrn target antibodi phase ii program delay due issu
recal laid clinic plan move pivot develop
waiha mg day march see note timelin
delay clinic program paus due discoveri impur
drug product compani expect initi trial
rest pipelin make progress phase ii/iii trial kappa/lambda light
chain antibodi al amloidosi expect compani begin earli pend
regulatori feedback copper chelat on-going pivot phase
focu trial could see data late long-lif bival
anti fcrn compound phase sad/mad data come
page analyst certif import disclosur
guggenheim secur llc research compani report
financi model updat
financi report revenu non-gaap ep ahead
consensu total revenu came q/q price volum
fx ahead consensu non-gaap ep
come q/q y/i ahead consensu estim
guidanc bump base today result manag increas revenu
guidanc non-gaap ep bracket consensu
look readili achiev also note compani note price headwind
metabol fx headwind
trend adjust
model updat reflect chang expect futur perform
current
respect
non-gaap ep estim
base chang forward price-to-earnings multipl
pt rais
page analyst certif import disclosur
guggenheim secur llc research compani report
page analyst certif import disclosur
agentindicationtrialpotenti catalysttimingstock antibodi nmosd n/apdufa action antibodi nmosd phase initi japanes sbla shorter infus time phase initi phase initi subq bridg ii/initi regulatori germani i/niti poc i/niti poc subq pk studi gravisn/aestim regulatori launch higher concentr subqu eu regulatori subq antibodi waihaphas ii/initi gravisphas ii/initi vulgarisphas initi diseasephas complet trial diseasephas final lal-dn/acontinu secur addit funding/reimburs inhibitor n/aphas i/iitoplin iiniti first human mab al amyloidosisphas ii/initi
page analyst certif import disclosur
ep cagrcompanytickerg ratingstock pricemcap guggenheim research factset compani report use consensu estim calcul price-to-earnings ratio exclud calculationselect biopharma companiesep p/erevenu multipl
figur valuat risk
pt assum alexion trade mean similar compani ep estim
support risk-adjust npv
forward price-to-earnings compar analysi yield pt valu share use forward price-to-earnings multipl
analysi look price-to-earnings multipl select biotech pharma compani similar invest
profil alexion compani trade consensu earn estim offer averag
ep compound-annual-growth-rate
project ep compound-annual-growth-rate think l-t sustain franchis light
competit remain concern therefor believ share unlik trade premium
peer appli mean multipl non-gaap ep prior ep arriv
pt
net-present-valu npv analysi support p/e-bas pt includ cash flow
alxn base busi approv product current net cash discount rate
termin growth rate
downsid risk includ failur secur approv soliri nmo slower expect growth
upsid risk includ substanti larger expect growth soliri sale nmo larg growth
pnh/ahu popul treatment
page analyst certif import disclosur
